Robotic Lung Cancer Surgery After Neoadjuvant Therapy

Two studies, two different evidence questions

Robotic lung resection research now includes both comparisons between operative approaches and early evaluations of new platforms. These questions should not be merged. One multicenter retrospective study compares robotic-assisted surgery with video-assisted thoracoscopic surgery after neoadjuvant chemoimmunotherapy for non-small cell lung cancer. A separate phase 1/2 single-arm registry evaluates whether a single-port robotic system can be used to perform lobectomy or segmentectomy. Neither design is a randomized head-to-head trial of all robotic systems.

The studies are relevant because post-neoadjuvant operations may present technical challenges, while new single-port systems aim to alter access and instrumentation. Yet a promising feasibility result does not establish comparative benefit, and a retrospective comparative association does not prove that the surgical platform caused the observed difference.

The multicenter comparison reports perioperative associations

The six-center study included 276 patients who underwent resection after neoadjuvant chemoimmunotherapy between 2019 and 2025. Most were approached robotically: 243 in the robotic group and 33 in the VATS group. The investigators applied inverse-probability weighting based on propensity scores. In the reported analysis, conversion to thoracotomy and major complications were higher with VATS, while overall complications and several oncologic measures were comparable.

These findings are specific to the included centers, treatment period, selection process, and adjustment model. The small VATS group relative to the robotic group leaves potential for unstable estimates, and weighting can address only measured differences. Residual confounding, surgeon and institutional experience, and selection of approach may remain. The paper supports further evaluation in the post-neoadjuvant setting, not a causal claim that robotic surgery is superior in all circumstances.

The single-port registry is an early feasibility signal

The SHURUI single-port study enrolled 35 adults with lung cancer in a phase 1/2 single-arm registry. The report states that lobectomy or segmentectomy was completed in all enrolled participants without conversion to VATS or open surgery, and describes short-term operative and hospital outcomes. Those results are useful for determining whether the system can be used in an initial clinical setting and for identifying what should be measured in larger studies.

Because the registry had no comparator and a small population, it cannot establish that the platform is safer, more effective, or more efficient than established approaches. A single-center or early experience can also reflect expert teams and carefully selected cases. The authors call for larger, multicenter randomized research to validate efficacy and safety in a broader population.

Keep technical feasibility separate from cancer outcomes

The comparative study reports similar measures such as resection quality and pathologic response between approaches in its cohort, while also reporting differences in conversion and major complication rates. These are not interchangeable outcomes. Technical completion, short-term morbidity, lymph-node assessment, and long-term recurrence each answer different questions and require distinct follow-up.

The single-port registry focuses on safety and feasibility, not comparative oncologic control. Its early results cannot be extended to long-term survival or to every robotic platform. Any summary should name the platform and study design, state the follow-up horizon, and avoid turning short-term observations into a general treatment recommendation.

What future studies should clarify

Prospective comparisons can improve confidence by prespecifying patient selection, conversion criteria, complication definitions, resection quality, and follow-up. In the post-neoadjuvant setting, studies should report how response, anatomy, and procedural complexity influence the choice of approach. They should also distinguish platform-specific learning curves from outcomes that may be reproducible across institutions.

Comparisons should report treatment response, extent of resection, nodal evaluation, pathologic findings, and the definition of major complications consistently. Patient-reported recovery and longer-term function may address questions not captured by technical measures alone. This helps separate differences associated with the platform from differences in the patients or teams selected for each approach.

For a new single-port system, multicenter enrollment and a comparator are important steps beyond initial feasibility. Longer follow-up is needed to characterize oncologic outcomes and late complications. The current studies help define those questions; they do not settle them.

A disciplined reading for clinical teams

When reviewing a proposed approach, ask whether the evidence is randomized, retrospective, or single-arm; how many patients received each procedure; how cases were selected; and which outcomes were measured. Check whether adjustment handled all relevant differences, whether the observed effect is short term, and whether the findings apply to the platform and patient group under discussion.

These publications support continued professional evaluation of robotic thoracic surgery, including after neoadjuvant chemoimmunotherapy. They do not provide individual medical advice or a universal procedural preference. Patient-specific decisions belong to the treating team with the complete clinical record and local expertise.